The PCA identified an understudied feature, the balance between mature glutamate receptor subunits (GluN2A:GluA2 balance), as a marker that might differentiate treatments supporting good acuity (BV), from those that lead to persistent bilateral amblyopia (RO, BD). Here, GRIA2 is linked to amblyopia.